4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Raised to $35.00

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price lifted by Royal Bank Of Canada from $32.00 to $35.00 in a report released on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also recently issued research reports about the company. Chardan Capital reissued a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Barclays began coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price target for the company. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.71.

4D Molecular Therapeutics Stock Down 4.1%

FDMT stock opened at $8.61 on Thursday. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $12.34. The company has a market cap of $439.54 million, a price-to-earnings ratio of -3.56 and a beta of 2.99. The company has a 50 day moving average of $8.75 and a two-hundred day moving average of $9.12.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The business had revenue of $85.09 million for the quarter, compared to analysts’ expectations of $30.86 million. On average, research analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently bought and sold shares of the stock. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter worth about $41,000. Farther Finance Advisors LLC raised its stake in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares in the last quarter. Abich Financial Wealth Management LLC acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $80,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in 4D Molecular Therapeutics in the 4th quarter worth approximately $77,000. 99.27% of the stock is currently owned by institutional investors.

Key 4D Molecular Therapeutics News

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.